Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Operating Leases (2016 - 2025)

Lineage Cell Therapeutics (LCTX) has 11 years of Operating Leases data on record, last reported at $1.3 million in Q4 2024.

  • For Q4 2024, Operating Leases fell 34.56% year-over-year to $1.3 million; the TTM value through Dec 2024 reached $1.3 million, down 34.56%, while the annual FY2024 figure was $1.3 million, 34.56% down from the prior year.
  • Operating Leases reached $1.3 million in Q4 2024 per LCTX's latest filing, down from $2.0 million in the prior quarter.
  • Across five years, Operating Leases topped out at $3.5 million in Q1 2020 and bottomed at $1.3 million in Q4 2024.
  • Average Operating Leases over 5 years is $2.2 million, with a median of $2.1 million recorded in 2021.
  • Peak YoY movement for Operating Leases: crashed 55.96% in 2020, then soared 57.92% in 2023.
  • A 5-year view of Operating Leases shows it stood at $2.5 million in 2020, then fell by 24.94% to $1.9 million in 2021, then skyrocketed by 51.56% to $2.9 million in 2022, then plummeted by 30.8% to $2.0 million in 2023, then plummeted by 34.56% to $1.3 million in 2024.
  • Per Business Quant database, its latest 3 readings for Operating Leases were $1.3 million in Q4 2024, $2.0 million in Q4 2023, and $2.0 million in Q3 2023.